- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.04. | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 03.04.2024 | 332 | Xetra Newsboard | The following instruments on XETRA do have their first trading 03.04.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.04.2024
Aktien
1 LU2791994721 Auna S.A.
2 US86959X1072... ► Artikel lesen | |
| 14.02. | Terumo Blood and Cell Technologies: Hundreds of sickle cell patients to benefit from £1.5M technology investment | 716 | PR Newswire | LONDON, Feb. 14, 2024 /PRNewswire/ -- Children, young people, and adults across England suffering from sickle cell disease will soon benefit from better care closer to where they live, following... ► Artikel lesen | |
| 08.02. | Terumo says revenue for nine months ended December 31 was ¥682.95B | 1 | Seeking Alpha | ||
| 13.12.23 | Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space | 2 | Zacks | ||
| 13.12.23 | Research and Markets: Europe Syringes & Needles Insights Report 2023: A $7.97 Billion Market in 2022 - Forecasts to 2028 with BD, CardinalHealth, B Braun, Nipro, and Terumo Dominating - ResearchAndMarkets.com | 403 | Business Wire | The "Europe Syringes Needles Market Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering.
In 2022, Europe Syringes and Needles market was valued at $7.97 billion... ► Artikel lesen | |
| 15.11.23 | Terumo reports 1H results | 6 | Seeking Alpha | ||
| 03.11.23 | Terumo Blood and Cell Technologies Names Jackie Kunzler Head of R&D | 4 | Contract Pharma |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 75,23 | -0,25 % | Medtronic's Inceptiv Spinal Cord Stimulator Receives FDA Approval To Treat Chronic Pain | FRIDLEY (dpa-AFX) - Friday, Medtronic plc (MDT) announced that the FDA has approved its Inceptiv closed-loop rechargeable spinal cord stimulator to treat chronic pain. The company said this... ► Artikel lesen | |
| HCA HEALTHCARE | 289,30 | +2,44 % | HCA Healthcare, Inc. Q1 Profit Increases, beats estimates | WASHINGTON (dpa-AFX) - HCA Healthcare, Inc. (HCA) released a profit for its first quarter that increased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| AMEDISYS | 84,50 | +0,60 % | Amedisys, Inc.: Amedisys Reports First Quarter 2024 Financial Results | BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March... ► Artikel lesen | |
| LANTHEUS | 62,62 | -0,19 % | Lantheus Holdings, Inc. - 8-K, Current Report | ||
| ENVISTA | 19,100 | +1,06 % | Envista Holdings Corporation: Envista Announces CEO Appointment | BREA, Calif., April 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) announced today the appointment of Paul Keel as Chief Executive Officer and a member of the Board of Directors... ► Artikel lesen | |
| CAREDX | 6,988 | -8,70 % | CareDx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| SYNEOS HEALTH | 40,000 | 0,00 % | Research and Markets: 2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report Featuring IQVIA, ICON, Parexel, Fortrea (formerly Labcorp), PPD/Thermo Fisher, and Syneos Health - ResearchAndMarkets.com | The "2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report" has been added to ResearchAndMarkets.com's offering.
The biopharmaceutical clinical development landscape... ► Artikel lesen | |
| GT BIOPHARMA | 3,170 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results | Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H... ► Artikel lesen | |
| CARMAT | 3,035 | -0,65 % | CARMAT Announces Its 2023 Annual Results and Provides an Update on Its Progress and Prospects for 2024 | 2023 sales of €2.8 million, i.e. 17 Aeson® implants, including 11 in the last quarter
2024 sales forecast of around €14 million
Active exploration of financing options to extend... ► Artikel lesen | |
| CHEMOMETEC | 39,220 | -3,06 % | Chemometec A/S: Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year | ANNOUNCEMENT NO. 261 Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year According to the preliminary figures, revenue in the third quarter... ► Artikel lesen | |
| HAMILTON THORNE | 0,925 | +0,54 % | Bloom Burton & Co. Inc.: Hamilton Thorne Ltd. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference | Beverly, Massachusetts--(Newsfile Corp. - April 10, 2024) - Hamilton Thorne Ltd. (TSX: HTL) (OTC Pink: HTLZF), Hamilton Thorne Ltd. a leading provider of precision instruments, laboratory equipment... ► Artikel lesen | |
| ARRAIL GROUP | 0,725 | -2,03 % | ARRAIL GROUP (06639): NEXT DAY DISCLOSURE RETURNS | ||
| DEVYSER DIAGNOSTICS | 8,020 | -3,61 % | Devyser Diagnostics AB: Devyser Diagnostics publishes year-end report for January to December 2023 | "Devyser is able to report strong sales growth and record high gross margins for the fourth quarter. During the quarter, Devyser continued to demonstrate the competitiveness of its products by winning... ► Artikel lesen | |
| POLAREAN IMAGING | 0,007 | -51,85 % | Polarean Imaging PLC - U.S. Patent granted for Xenon MRI | ||
| SIEMENS HEALTHINEERS | 52,22 | -0,99 % | DZ BANK stuft Siemens Healthineers auf 'Halten' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Siemens Healthineers vor Zahlen von 52 auf 53 Euro angehoben und die Einstufung auf "Halten" belassen. Analyst Sven Kürten erwartet... ► Artikel lesen |
Das Unternehmen TERUMO CORPORATION ADR kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 15,300 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
